Pineal Parenchymal Tumors: Clinical and Molecular Insights

Pineal parenchymal tumours encompass a spectrum of rare neoplasms arising from the secretory cells of the pineal gland, ranging from low‐grade pineocytomas through intermediate differentiation to highly malignant pineoblastomas. Clinically, these tumours present with signs of raised intracranial pressure, Parinaud’s syndrome and endocrine disturbances owing to local mass effect and hydrocephalus. Radiological features vary according to grade, with magnetic resonance imaging offering detailed insight into tissue characteristics and contrast enhancement patterns. Histological assessment remains crucial, revealing divergent architectures—sheets of small round cells in pineoblastoma, papillary structures in papillary tumours of the pineal region (PTPR) and lobulated nests in pineocytoma. In recent years, multilayered molecular profiling has uncovered distinct epigenetic and genetic subgroups that refine prognostic stratification and suggest targeted therapeutic avenues. Key discoveries include age‐dependent methylation clusters, recurrent chromosomal imbalances and mutations affecting microRNA biogenesis and chromatin regulation. Integrating these molecular markers with surgical, radiotherapeutic and chemotherapeutic approaches has begun to improve outcome predictions and to inform collaborative trial design across paediatric and adult populations.

Research from Nature Portfolio

Recent genomic and epigenomic analyses have advanced understanding of pineoblastoma. One comprehensive study examined paediatric and adult cases using genome‐wide methylation and exome sequencing, revealing age‐specific methylation clusters that in adults overlap with lower‐grade lesions and normal tissue. Recurrent alterations included homozygous loss of the microRNA processor DROSHA and focal gain of PDE4DIP, implicating microRNA dysregulation and DUF1220 domain amplification in tumourigenesis. Additional variants in PKA and NF-κB signalling pathways, together with aberrations in chromatin-remodelling genes, offer novel targets for therapeutic intervention.

Pineal Parenchymal Tumors: Clinical and Molecular Insights publication trend

The graph below shows the total number of articles in pineal parenchymal tumors: clinical and molecular insights across all publications each year (not limited to Nature Index journals).

Technical terms

Pineoblastoma: A high‐grade, highly aggressive pineal parenchymal tumour composed of primitive neuroectodermal cells.

Pineocytoma: A benign, slow-growing pineal parenchymal tumour characterised by well-differentiated pinealocytes.

Pineal parenchymal tumour of intermediate differentiation (PPTID): A lesion with features between pineocytoma and pineoblastoma, showing moderate mitotic activity.

Papillary tumour of the pineal region (PTPR): A distinct entity with papillary histology, defined by specialised ependymal-like cells and unique methylation profiles.

DNA methylation profiling: Genome-wide assessment of cytosine methylation patterns used to classify tumours into molecular subgroups.

Homozygous deletion: Loss of both chromosomal copies of a gene locus, resulting in loss of gene function.

Microduplication: A small-scale duplication of a genomic region, increasing copy number of contained genes.

DROSHA: An RNase III enzyme critical for the initial processing of primary microRNA transcripts.

PDE4DIP: Gene encoding myomegalin, whose amplification can dysregulate cyclic AMP signalling in tumours.

References

1. Papillary tumor of the pineal region: analysis of DNA methylation profiles and clinical outcomes in 76 cases. Acta Neuropathologica Communications (2024).
2. Post-Surgical Prognosis of Patients with Pineoblastoma: A Systematic Review and Individual Patient Data Analysis with Trends over Time. Cancers (2023).
3. Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. Nature Communications (2018).
4. Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances (2022).